Key result
Roux-en-Y gastric bypass surgery led to a 35 kg weight loss, decreased late OGTT plasma glucose, and an 84% increase in β-cell secretion correlated with a 29-fold elevation in GLP-1.
Why the study?
Does Roux-en-Y gastric bypass surgery improve whole-body insulin sensitivity and beta-cell function in nondiabetic morbidly obese patients?
Observational (n=18)
Does Roux-en-Y gastric bypass surgery improve whole-body insulin sensitivity and beta-cell function in nondiabetic morbidly obese patients?
Answers are grounded in this paper and cite their sources.
RYGB surgery in morbidly obese patients significantly increases GLP-1 release and beta-cell function, improving insulin sensitivity to levels comparable to obese controls.
OBJECTIVE: Obesity leads to severe long-term complications and reduced life expectancy. Roux-en-Y gastric bypass (RYGB) surgery induces excessive and continuous weight loss in (morbid) obesity, although it causes several abnormal anatomical and physiological conditions. RESEARCH DESIGN AND METHODS: To distinctively unveil effects of RYGB surgery on β-cell function and glucose turnover in skeletal muscle, liver, and gut, nondiabetic, morbidly obese patients were studied before (pre-OP, five female/one male, BMI: 49 ± 3 kg/m(2), 43 ± 2 years of age) and 7 ± 1 months after (post-OP, BMI: 37 ± 3 kg/m(2)) RYGB surgery, compared with matching obese (CON(ob), five female/one male, BMI: 34 ± 1 kg/m(2), 48 ± 3 years of age) and lean controls (CON(lean), five female/one male, BMI: 22 ± 0 kg/m(2), 42 ± 2 years of age). Oral glucose tolerance tests (OGTTs), hyperinsulinemic-isoglycemic clamp tests, and mechanistic mathematical modeling allowed determination of whole-body insulin sensitivity (M/I), OGTT and clamp test β-cell function, and gastrointestinal glucose absorption. RESULTS: Post-OP lost (P < 0.0001) 35 ± 3 kg body weight. M/I increased after RYGB, becoming comparable to CON(ob), but remaining markedly lower than CON(lean) (P < 0.05). M/I tightly correlated (τ = -0.611, P < 0.0001) with fat mass. During OGTT, post-OP showed ≥15% reduced plasma glucose from 120 to 180 min (≤4.5 mmol/L), and 29-fold elevated active glucagon-like peptide-1 (GLP-1) dynamic areas under the curve, which tightly correlated (r = 0.837, P < 0.001) with 84% increased β-cell secretion. Insulinogenic index (0-30 min) in post-OP was ≥29% greater (P < 0.04). At fasting, post-OP showed approximately halved insulin secretion (P < 0.05 vs. pre-OP). Insulin-stimulated insulin secretion in post-OP was 52% higher than before surgery, but 1-2 pmol/min(2) lower than in CON(ob)/CON(lean) (P < 0.05). Gastrointestinal glucose absorption was comparable in pre-OP and post-OP, but 9-26% lower from 40 to 90 min in post-OP than in CON(ob)/CON(lean) (P < 0.04). CONCLUSIONS: RYGB surgery leads to decreased plasma glucose concentrations in the third OGTT hour and exaggerated β-cell function, for which increased GLP-1 release seems responsible, whereas gastrointestinal glucose absorption remains unchanged but lower than in matching controls.
No takes yet. Share an insight, caveat, or question.
Anderwald et al. (2012) conducted an observational in Nondiabetic, morbidly obese (n=18). Roux-en-Y gastric bypass (RYGB) surgery vs. Pre-operative state, obese controls, and lean controls was evaluated on β-cell function, glucose turnover, whole-body insulin sensitivity, and gastrointestinal glucose absorption. Roux-en-Y gastric bypass surgery led to a 35 kg weight loss, decreased late OGTT plasma glucose, and an 84% increase in β-cell secretion correlated with a 29-fold elevation in GLP-1.
Synapse has enriched 10 related papers. Consider them for comparative context: